TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12414874

Group type: EXPERIMENTAL
Intervention: Aspirin (a nonspecific COX‐1 and COX‐2 inhibitor)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diclofenac (predominantly a COX‐2 inhibitor)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Celecoxib (a specific COX‐2 inhibitor)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9682122

Group type: COMPARATOR
Intervention: 10‐1 nylon anchor suture
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: cyanoacrylate (Histoacryl)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: fibrinogen (Tissucol)
Number of subjects: 126
Study: 7887333

Group type: EXPERIMENTAL
Intervention: Frequency-doubled Nd:YAG laser
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Krypton laser
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diode laser
Number of subjects: 13
Study: 2403834

Group type: EXPERIMENTAL
Intervention: CMFPT
Number of subjects: 553

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 553
Study: 755865

Group type: EXPERIMENTAL
Intervention: autogenic training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: combination of autogenic training and skin temperature feedback
Number of subjects: 30
Study: 31616975

Group type: EXPERIMENTAL
Intervention: Columellar strut graft
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tongue-in-groove
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 31127818

Group type: EXPERIMENTAL
Intervention: Fat delivered to the distal small intestine in delayed release microcapsules
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate or protein delivered in gastric release formulations
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fat delivered in gastric release formulations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Food intake after consumption of fat at distal small intestine
Number of subjects: 8
Study: 29220633

Group type: EXPERIMENTAL
Intervention: suicide‐focused intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: treatment‐as‐usual condition
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: comprehensive and multimodal suicide‐focused intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: flexible and theoretically agnostic suicide‐focused intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: overall SMART approach
Number of subjects: 62
Study: 26011337

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Postoperative parenteral nutrition (PN)
Number of subjects: 400
Study: 23420502

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no ergocalciferol)
Number of subjects: 20
Study: 21289227

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels measured in quartiles and clinical cut points (<50, 50-<75, ≥ 75 nmol/L)
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: 25(OH)D levels as a continuous variable
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: Evaluation by strata of BMI, race/ethnicity, or randomization status in the Calcium Vitamin D trial
Number of subjects: 5140
Study: 19472447

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10-mg ODT
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Rizatriptan + education
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Rizatriptan + no education
Number of subjects: 207
Study: 17904942

Group type: EXPERIMENTAL
Intervention: Traditional detailed self-monitoring method
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Abbreviated self-monitoring method
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self-monitoring diaries completed
Number of subjects: 42
Study: 15180119

Group type: EXPERIMENTAL
Intervention: Lateral tangential focusing with ultrasound-guided ESWT
Number of subjects: 41

Group type: COMPARATOR
Intervention: Back tangential focusing with ultrasound-guided ESWT
Number of subjects: 41
Study: 11679918

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoids-acellular pertussis (DTaP) combined with PRP-tetanus conjugate (PRP-T) vaccine
Number of subjects: 0
Study: 9575391

Group type: EXPERIMENTAL
Intervention: Healthy adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individuals with chronic illnesses (multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly individuals
Number of subjects: 0
Study: 7841965

Group type: EXPERIMENTAL
Intervention: Drug treatment alone
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Both drug and surgical treatment (endometrial resection or hysterectomy)
Number of subjects: 309
Study: 3347762

Group type: EXPERIMENTAL
Intervention: Contingent instruction
Number of subjects: 61

Group type: COMPARATOR
Intervention: Noncontingent instruction
Number of subjects: 61
Study: 30251598

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg single oral dose
Number of subjects: 32
Study: 27440518

Group type: EXPERIMENTAL
Intervention: 30 mg edoxaban
Number of subjects: 8292

Group type: EXPERIMENTAL
Intervention: 60 mg edoxaban
Number of subjects: 8292

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 8292
Study: 25427999

Group type: EXPERIMENTAL
Intervention: Resistance training group (TG; n=16)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG; n=10)
Number of subjects: 26
Study: 23448939

Group type: EXPERIMENTAL
Intervention: Phytonutrient supplement (blended fruit and vegetable juice powder concentrate)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Phytonutrient supplement
Number of subjects: 684
Study: 20873911

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) group (n = 42)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) group (n = 74)
Number of subjects: 116
Study: 18487886

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 0
Study: 16759511

Group type: EXPERIMENTAL
Intervention: Prophylactic group (PG) receiving curosurf immediately after admission
Number of subjects: 100
Study: 14551843

Group type: EXPERIMENTAL
Intervention: Patella resurfacing during total knee arthroplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: No patella resurfacing during total knee arthroplasty
Number of subjects: 50
Study: 11641316

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 9410284

Group type: EXPERIMENTAL
Intervention: Gasp maneuver for inspiratory muscle strength measurement in ILD patients with normal static compliance (group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gasp maneuver for inspiratory muscle strength measurement in ILD patients with decreased static compliance (group B)
Number of subjects: 18
Study: 1314192

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3971673

Group type: EXPERIMENTAL
Intervention: Fat-free mass estimation using body weight and skinfold thickness
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Total body potassium and nitrogen measurements
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Factor analysis of fat-free tissue measures
Number of subjects: 104
Study: 29891397

Group type: EXPERIMENTAL
Intervention: Nasal irrigation (NaCl .9%) followed by forced nasal inspiration
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal activities (Control Group)
Number of subjects: 44
Study: 28763413

Group type: EXPERIMENTAL
Intervention: Motor-sparing block (0.5% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Periarticular infiltration (0.3% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Motor-sparing block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Periarticular infiltration
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Motor-sparing block and periarticular infiltration
Number of subjects: 82
Study: 25777669

Group type: EXPERIMENTAL
Intervention: Screening arm (serum PSA reading)
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Control arm (no diagnostic tests)
Number of subjects: 4276

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 4276

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 4276
Study: 23347176

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg every other day plus folic acid 5 mg daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Tadalafil 10 mg every other day plus placebo daily
Number of subjects: 83
Study: 21181186

Group type: EXPERIMENTAL
Intervention: NSAID group (n = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-NSAID group (n = 14)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NSAID group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 19927474

Group type: EXPERIMENTAL
Intervention: Patients rated themselves as having good adherence
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Clinicians rated patients as having good adherence
Number of subjects: 238
Study: 17912163

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary interventions (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (under investigation)
Number of subjects: 0
Study: 12786728

Group type: EXPERIMENTAL
Intervention: Deodorants containing hydroxycitronellal (0.032-0.32%) applied twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (patients without contact allergy to hydroxycitronellal)
Number of subjects: 14
Study: 10473959

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.05%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Emollient (control group)
Number of subjects: 21
Study: 8659014

Group type: EXPERIMENTAL
Intervention: Kidney transplantation without prior nephrectomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Matched controls (with prior nephrectomy)
Number of subjects: 47
Study: 1761173

Group type: EXPERIMENTAL
Intervention: 1 mg oestriol applied daily intravaginally over 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 mg oestriol applied daily intravaginally over 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7183191

Group type: EXPERIMENTAL
Intervention: Self-monitoring group 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-monitoring group 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-monitoring group 3
Number of subjects: 50

Group type: COMPARATOR
Intervention: No self-monitoring control group 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: No self-monitoring control group 2
Number of subjects: 50
Study: 6234146

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Culdoscopy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 300
Study: 29959111

Group type: EXPERIMENTAL
Intervention: My Tools 4 Care (MT4C)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 199
Study: 27005980

Group type: EXPERIMENTAL
Intervention: TAVR (self-expandable bioprosthesis)
Number of subjects: 280

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: TAVR with severe PPM
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: SAVR with severe PPM
Number of subjects: 280
Study: 24366034

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Combination (weight loss and sodium reduction)
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Sodium intake maintenance
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Weight loss and sodium reduction
Number of subjects: 1820
Study: 23158073

Group type: EXPERIMENTAL
Intervention: nCPAP + antihypertensive drugs
Number of subjects: 980

Group type: COMPARATOR
Intervention: Antihypertensive drugs only
Number of subjects: 980
Study: 20490904

Group type: EXPERIMENTAL
Intervention: Hydralazine therapy (25 mg b.d., for 1 week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydralazine therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study: 18300848

Group type: EXPERIMENTAL
Intervention: Valsartan 80-160 mg/day
Number of subjects: 15245

Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg/day
Number of subjects: 15245
Study: 16113620

Group type: EXPERIMENTAL
Intervention: Atomoxetine monotherapy
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combined atomoxetine/fluoxetine therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Fluoxetine (with concomitant atomoxetine)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (with concomitant atomoxetine)
Number of subjects: 173
Study: 12885837

Group type: EXPERIMENTAL
Intervention: 30-minute infusion of gemcitabine (2,200 mg/m2)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fixed dose rate (FDR) infusion of gemcitabine (1,500 mg/m2 over 150 minutes)
Number of subjects: 92
Study: 10389788

Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 80
Study: 8782169

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Selective adsorption using a tryptophan-linked polyvinyl alcohol gel adsorbent
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Selective adsorption followed by intravenous IgG
Number of subjects: 45
Study: 1653660

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6344265

Group type: EXPERIMENTAL
Intervention: Diazepam 0.05 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 30642575

Group type: EXPERIMENTAL
Intervention: BET inhibitor (JQ1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computational biology modeling (CBM) predictions
Number of subjects: 100
Study: 29551706

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 8 weeks (300 mg/120 mg)
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 12 weeks (300 mg/120 mg)
Number of subjects: 2041
Study: 26400416

Group type: EXPERIMENTAL
Intervention: Interval walking training in water (WG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Interval walking training on land (LG)
Number of subjects: 31
Study: 25296339

Group type: EXPERIMENTAL
Intervention: Snus users
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-snus users
Number of subjects: 80
Study: 22828556

Group type: EXPERIMENTAL
Intervention: Ringer's Lactate 20ml/kg (Group-RL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch-6% 8ml/kg (Group-H)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Ringer's Lactate 10ml/kg and Hydroxyethylstarch-6% 4ml/kg (Group-RLH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Group-RL)
Number of subjects: 90
Study: 20430429

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 170432

Group type: COMPARATOR
Intervention: Control group (not contacted)
Number of subjects: 170432
Study: 17490966

Group type: EXPERIMENTAL
Intervention: Trace element supplementation (copper, selenium, zinc) administered intravenously for 14-21 days.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trace element supplementation (TE group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trace element supplementation
Number of subjects: 21
Study: 16224034

Group type: EXPERIMENTAL
Intervention: Standard technique
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Standard technique facilitated with gastric insufflation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Standard technique facilitated with the use of preinsertion erythromycin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 75
Study: 15561864

Group type: EXPERIMENTAL
Intervention: BB-83698 (10 to 475 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10780242

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8526579

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (400 mL, 285 mOsm/kg, 12.0% carbohydrates)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (400 mL)
Number of subjects: 12
Study: 6908961

Group type: EXPERIMENTAL
Intervention: Unlocked car door condition
Number of subjects: 116

Group type: COMPARATOR
Intervention: Locked car door condition
Number of subjects: 116
Study: 31270740

Group type: EXPERIMENTAL
Intervention: Progressive intradialytic resistance exercise (high or moderate intensity for 12 weeks, 3 times per week)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Progressive intradialytic resistance exercise
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine hemodialysis care
Number of subjects: 41
Study: 28806217

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous ondansetron
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 25403582

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 6 months for 3 years) plus tamoxifen (20 mg/day)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 6 months for 3 years) plus anastrozole (1 mg/day)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 1803
Study: 23811948

Group type: EXPERIMENTAL
Intervention: Aquatic training (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Land training (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Aquatic and Land)
Number of subjects: 30
Study: 21314924

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 19420314

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP), 8 sessions over 4 months
Number of subjects: 0
Study: 16704287

Group type: EXPERIMENTAL
Intervention: Asthma education program for rural school nurses
Number of subjects: 7
Study: 15191584

Group type: EXPERIMENTAL
Intervention: Plastic scraper
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nylon multi‐tufted toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no tongue cleaning)
Number of subjects: 16
Study: 11132749

Group type: EXPERIMENTAL
Intervention: Nicardipine 0.017 mg x kg(‐1) administered as a bolus
Number of subjects: 20
Study: 9323693

Group type: EXPERIMENTAL
Intervention: 20% soybean fat emulsion with 10% marine fish oil emulsion
Number of subjects: 19

Group type: COMPARATOR
Intervention: 20% soybean fat emulsion
Number of subjects: 19
Study: 8406060

Group type: EXPERIMENTAL
Intervention: Nicotine (2-4 mg in gum base)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 3778815

Group type: EXPERIMENTAL
Intervention: Behavioural method of habit reversal combined with hydrocortisone cream
Number of subjects: 17

Group type: COMPARATOR
Intervention: Regular ointment treatment (hydrocortisone cream alone)
Number of subjects: 17
Study: 30081859

Group type: EXPERIMENTAL
Intervention: 2 mg per night of capsulated sustained-release melatonin (Circadin)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1 placebo capsule
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline (no treatment)
Number of subjects: 34
Study: 27274009

Group type: EXPERIMENTAL
Intervention: Pradigastat (115 mg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg oral, positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25738335

Group type: EXPERIMENTAL
Intervention: Conical interface (CI; OsseoSpeed, Dentsply Implants), n = 4
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Flat-to-flat interface (FI; NobelSpeedy Replace, Nobel Biocare), n = 4
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Platform-switch interface (PS; NanoTite Certain Prevail, Biomet 3i), n = 4
Number of subjects: 141
Study: 22531616

Group type: EXPERIMENTAL
Intervention: Combined rugby conditioning plyometric program (4 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonplyometric rugby conditioning program (control group)
Number of subjects: 35
Study: 21840915

Group type: EXPERIMENTAL
Intervention: telephone cognitive behavioural therapy emphasizing physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 0
Study: 19842352

Group type: EXPERIMENTAL
Intervention: New treatment consisting of stretching, posture training, and auricular acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 24
Study: 17101889

Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support intervention
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406